Literature DB >> 16920490

Signal integration between IFNgamma and TLR signalling pathways in macrophages.

Kate Schroder1, Matthew J Sweet, David A Hume.   

Abstract

Macrophages are major effector cells of the innate immune system, and appropriate regulation of macrophage function requires the integration of multiple signalling inputs derived from the recognition of host factors (e.g. interferon-gamma/IFNgamma) and pathogen products (e.g. toll-like receptor/TLR agonists). The profound effects of IFNgamma pre-treatment ("priming") on TLR-induced macrophage activation have long been recognised, but many of the mechanisms underlying the priming phenotype have only recently been identified. This review summarises the known mechanisms of integration between the IFNgamma and TLR signalling pathways. Synergy occurs at multiple levels, ranging from signal recognition to convergence of signals at the promoters of target genes. In particular, the cross-talk between the IFNgamma, and LPS and CpG DNA signalling pathways is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920490     DOI: 10.1016/j.imbio.2006.05.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  125 in total

1.  Cell surface trafficking of TLR1 is differentially regulated by the chaperones PRAT4A and PRAT4B.

Authors:  Bryan E Hart; Richard I Tapping
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

Review 2.  Integration of cytokine and heterologous receptor signaling pathways.

Authors:  Jelena S Bezbradica; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 3.  Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection.

Authors:  William J Crisler; Laurel L Lenz
Journal:  Curr Opin Immunol       Date:  2018-06-07       Impact factor: 7.486

4.  IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Authors:  Barbara Dillinger; Sarah Ahmadi-Erber; Manuel Lau; Markus A Hoelzl; Friedrich Erhart; Birgit Juergens; Dietmar Fuchs; Andreas Heitger; Stephan Ladisch; Alexander M Dohnal
Journal:  Cell Immunol       Date:  2018-02-02       Impact factor: 4.868

5.  Effects of strains of Lactococcus lactis on the production of nitric oxide and cytokines in murine macrophages.

Authors:  Chise Suzuki; Ayako Aoki-Yoshida; Hiromi Kimoto-Nira; Miho Kobayashi; Keisuke Sasaki; Koko Mizumachi
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

6.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

7.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.

Authors:  Mirjana Urosevic; Kazuyasu Fujii; Bastien Calmels; Elisabeth Laine; Nikita Kobert; Bruce Acres; Reinhard Dummer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

8.  Glial restricted precursors maintain their permissive properties after long-term expansion but not following exposure to pro-inflammatory factors.

Authors:  Kazuo Hayakawa; Christopher Haas; Ying Jin; Julien Bouyer; Takanobu Otsuka; Itzhak Fischer
Journal:  Brain Res       Date:  2015-10-21       Impact factor: 3.252

Review 9.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases.

Authors:  Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Immunity       Date:  2009-10-16       Impact factor: 31.745

10.  Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis.

Authors:  Hongmei Li; Bogoljub Ciric; Jingxian Yang; Hui Xu; Denise C Fitzgerald; Mohamed Elbehi; Zoe Fonseca-Kelly; Shuo Yu; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2009-02-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.